The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Killing on average over 100,000 children across the world per year, respiratory syncytial virus (RSV) is the second greatest cause of death by a single pathogen for children under one year of age ...

Palivizumab, when given through the veins or into a muscle (systemically), reduces hospitalisations due to respiratory syncytial virus (RSV) and reduces respiratory problems later on (chest wheezing), ...

In a retrospective study published in the Journal of the American Geriatrics Society, adults aged 65 and older hospitalized for RSV in Ontario, Canada experienced significantly higher rates of adverse ...

Respiratory syncytial virus (RSV) causes a viral infection of the respiratory system similar to that of a cold and cough. It is a common illness and will affect most children at least once by the ...

A. Respiratory syncytial virus is a virus that most children have been exposed to by the time they're 2 years old. Symptoms vary from just a mild cold to bronchiolitis, ...

Covid-19 will probably account for half of those new hospitalizations, with flu and respiratory syncytial virus (RSV) combined accounting for the other half.

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...